Genmab — Juni 2019

Darvin

Som jeg læser teksten er de langt. De har gode prekliniske data og som de skriver could be superior to daratumumab for certain tumor cell types. Måske ikke langt fra at de er klar til næste skridt.

Bulder

@E L: I think it's developing, not co-developing. If Janssen exercises the option they'll take over all the costs - as I see it.

E_L

oh really, i read that wrong then; that is a BIG difference!

E_L

think you are correct. makes sense also really, given the current Dara deal, they are extending and improving that

JKY_VH

Enig Bulder, det er vel ret beset også det Ritzau skriver "Baseret på data fra Genmabs studier, kan Janssen så vælge at udnytte sin option på at udvikle, fremstille og markedsføre Hexabody-CD38. Sker det, vil Janssen betale Genmab 150 mio. dollar, eller knap 1 mia. kr., for at udnytte optionen."

kkjoel

Ja, de overtager (udvikling OG omkostninger): "Based on the data from these studies, Janssen may exercise its option and receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38." Sådan må man læse det.

JKY_VH

præcis

E_L

And it was all predicted here before! "10/4 11:07
af Sukkeralf
That should maybe be hexaboost as life cicle management" "well, yes, that would be an interesting development; are you thinking a HexaDara to increase patent life and some extra Hexa licencing money? I like it "

Bulder

Har vi hørt om hexabody cd38 før? Jeg synes ikke at kunne finde nogen IND/CTA undervejs?

E_L

i haven't seen it before, no

E_L

next question is; will it work in solids

bibob

Lets hope so.

Bulder

There is not that much cd38 on solid tumors. The reason why dara was thought to be effective in solids was that it could strengthen the efficacy of a PD(L)-1 inhibitor by blocking cd38. I don't know if a boosted cd38 would be of any help here. But I think we need Sukkeralf on this subject.

Sukkeralf

If I remember correctly Jans first thoughts of new INDs for 2019 was 3-5 and recently it was 3 (and we know them all) but maybe HexaCD38 could have been close so I hope it will be a 2020 IND

lahn1

@09:28 yes I see that now. It stille feels early to do this deal, hence the "pure milestone
payement"

Sukkeralf

But the deal need to be in place for Genmab to do the costly preclinical work

lahn1

yes nice to have a buyer on hand, maybe not as bad a deal as it seemed at first glance

nohope

I´ll welcome almost any kind of deals, also, this deal, but it does seem rather far away from what Jan has been talking about. This is a techdeal with a product, this should have been paid upfront and/or on 50/50 basis. But any hole in the no-deal-wall is welcome to me.

E_L

I am actually very excited about this deal- Dara is the backbone of this company and Genmab is looking to strengthen and extend that backbone. Extremely important and a sign of mature management with a long term view imo. I really like Sukkeralf's term 'life cycle management' in this respect.

E_L

@nohope 09:21 is my answer to that.